Search

Your search keyword '"Heidel, Florian"' showing total 871 results

Search Constraints

Start Over You searched for: Author "Heidel, Florian" Remove constraint Author: "Heidel, Florian"
871 results on '"Heidel, Florian"'

Search Results

3. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

4. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

5. Adressen

9. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany

11. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia

12. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

16. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

18. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

24. Characteristics of hospital admission during checkpoint-inhibition therapy.

26. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML

28. Breakthrough infections in MPN-COVID vaccinated patients

29. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

33. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

37. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

39. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations

41. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

42. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

43. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

44. Associations of spleen volume with markers of blood count and lipid profile in a large population-based study

45. P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)

46. S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q

49. Gynäkologische Tumoren

50. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Catalog

Books, media, physical & digital resources